United States · 
What does Decheng Capital invest in?
Decheng Capital invests most often at Series A and Series B (69% of the rounds on record), in sectors such as Life Sciences and Healthcare.
Decheng Capital highlights
- 01
2 cheques in the last 12 months
- 02
Mostly Series A and Series B: 69% of its rounds
- 03
Sole investor in 6 rounds, median $19M
- 04
1 exits from the portfolio
What they do
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Life SciencesHealthcare
- Based in
- Menlo Park, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first17 appearances
- 2026
2 rounds
- Sept
- Apr
- 2024
1 round
- Dec
- 2019
4 rounds
- Dec
- Oct
- May
- May
- 2018
3 rounds
- Sept
- Aug
- Jul
- 2017
2 rounds
- Nov
- May
- 2016
1 round
- Sept
- 2014
2 rounds
- Oct
- Jun
- 2013
1 round
- Nov
- 2012
1 round
- Feb
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration5 named
FYFengying YuManageriFiling they signed
HBHongbo BaoChief Compliance OfficeriForm ADV
XCXiangmin CuiDirector of General PartneriFiling they signed
XMXiangmin MinDirector of General PartneriFiling they signed
YQYuheng QiuManageriFiling they signed
We also hold 18 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$2.7Bassets it managesOct 2026
4+funds on filenumbered funds in its name
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Decheng Capital LLC
- SEC number
- CRD 293073
Funds on its Form ADV
5 private funds, $1.8B in gross assets · filed Aug 2024
Venture 4Hedge 1
- Decheng Capital China Life Sciences USD Fund III, L.P.Venture34 investors$612M
- Decheng Capital Global Life Sciences Fund IV, L.P.Venture42 investors$511M
- Decheng Capital China Life Sciences USD Fund II, L.P.Venture38 investors$376M
- Decheng Capital Global Healthcare Fund (Master), L.P.Hedge16 investors$166M
- Decheng Capital China Life Sciences USD Fund I, L.P.Venture21 investors$126M
What they claim to have backed
From their own portfolio page (on their website)
29 of 55 we have independently watched raise
ACELYRINAdaptive BiotechnologiesAdelaAlpine Immune SciencesAnHeart TherapeuticsArcus BiosciencesArk BiosciencesCG OncologyCellaresCue HealthEpimAb BiotherapeuticsEverest MedicinesGRIT BiotechnologyHummingbird BioscienceIMPACT TherapeuticsImmPACT BioInvitaeKeChow PharmaLevitasBioMammoth BiosciencesMirvieNalu MedicalOmniomePackGene BiotechPolares MedicalScynexisTerns PharmaceuticalUpstream BioWatchmaker Genomics3SBioAK MedicalAadiAadiAccuragenAlbireo PharmaBCFoodsBeyondSpring PharmaceuticalsBiohengCentricity VisionConjugateBioEncodiaEquillium BioFirefly BiologicsGRAILHarton TherapeuticsInsight LifetechKind PharmaceuticalsLYNK PharmaceuticalsMedical CreationsSINO Medical Sciences TechnologyShanghai Legend MedicalTake2USCI Medical LaboratoryVintaBioZentalis
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed1 in all
GeneWEAVEBought by Roche$425MAug 2015
An exit counts when it came after the firm's first round in the company. From historical deal records.